EZH2 and lymphoma: Given the previously published work looking at EZH2 inhibition in lymphoma over longer time periods, we extended our viability assays to 6 days using EPZ005687 at lower concentrations.44, 49 We demonstrated a reduction in viability following EZH2 inhibition, at this time point, in most cell lines using the WST-1 viability assay (Figure 2c) with no evidence of response in only 2/8 cell lines (JIM3 and U266).